Evidence map›Paper›PMID 39013872›Full record

ArticleNPJ systems biology and applications2024

Systems modeling of oncogenic G-protein and GPCR signaling reveals unexpected differences in downstream pathway activation.

Michael Trogdon, Kodye Abbott, Nadia Arang, Kathryn Lande, Navneet Kaur, Melinda Tong, Mathieu Bakhoum, J Silvio Gutkind, Edward C Stites

Abstract read
In one paragraph

Article in NPJ systems biology and applications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michael TrogdonIntegrative Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, 92037, USA.
Kodye AbbottDepartment of Laboratory Medicine, Yale School of Medicine, New Haven, CT, 06520, USA.ORCID http://orcid.org/0000-0002-1439-1060
Nadia ArangMoores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA.
Kathryn LandeRazavi Newman Integrative Genomics and Bioinformatics Core, Salk Institute for Biological Studies, La Jolla, CA, 92037, USA.
Navneet KaurDepartment of Laboratory Medicine, Yale School of Medicine, New Haven, CT, 06520, USA.ORCID http://orcid.org/0000-0001-6821-314X
Melinda TongIntegrative Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, 92037, USA.
Mathieu BakhoumDepartment of Ophthalmology and Visual Science, Yale School of Medicine, New Haven, CT, 06520, USA.
J Silvio GutkindMoores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0000-0002-5150-4482
Edward C StitesDepartment of Laboratory Medicine, Yale School of Medicine, New Haven, CT, 06520, USA. edward.stites@yale.edu.ORCID http://orcid.org/0000-0002-3783-7336

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Salk Institute Cancer Training GrantT32CA009370 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Diana Clare Hargreaves, Jan Karlseder · 1986 to 2026
$8.6M
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal MelanomaR01CA257505 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI APLIN, ANDREW ERIC, GUTKIND, JORGE SILVIO · 2021 to 2025
$2.7M
Systems Approaches for Opening Therapeutic WindowsDP2AT011327 · NCCIH · YALE UNIVERSITY · PI STITES, EDWARD C. · 2020 to 2020
$2.6M
NCATS NIH HHS UL1 TR001863NCCIH NIH HHS DP2 AT011327NCI NIH HHS R01 CA257505NCI NIH HHS T32 CA009370U.S. Department of Health & Human Services | National Institutes of Health (NIH) DP2AT011327U.S. Department of Health & Human Services | National Institutes of Health (NIH) T32CA009370
6 · The paper itself

Abstract

Mathematical models of biochemical reaction networks are an important and emerging tool for the study of cell signaling networks involved in disease processes. One promising potential application of such mathematical models is the study of how disease-causing mutations promote the signaling phenotype that contributes to the disease. It is commonly assumed that one must have a thorough characterization of the network readily available for mathematical modeling to be useful, but we hypothesized that mathematical modeling could be useful when there is incomplete knowledge and that it could be a tool for discovery that opens new areas for further exploration. In the present study, we first develop a mechanistic mathematical model of a G-protein coupled receptor signaling network that is mutated in almost all cases of uveal melanoma and use model-driven explorations to uncover and explore multiple new areas for investigating this disease. Modeling the two major, mutually-exclusive, oncogenic mutations (Gα

Indexed as

MutationReceptors, G-Protein-CoupledSignal TransductionGTP-Binding ProteinsHumansMelanomaModels, BiologicalSystems BiologyUveal MelanomaUveal NeoplasmsGTP-Binding ProteinsReceptors, G-Protein-Coupled

Identifiers

PMID39013872
PMCPMC11252164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.